COMMUNIQUÉS West-GlobeNewswire

BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
12/03/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 12, 2026 (GLOBE NEWSWIRE) -- Under the BioVersys and GSK collaboration agreement, AlpE clinical development advances with first patient dosed in Phase [...]
Full Year 2025 Trading Update
12/03/2026
Ad hoc announcement pursuant to Art. 53 LR AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth Pratteln, Switzerland, March 12, 2026 – Santhera Pharmaceuticals (SIX: SANN) today provides [...]
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
12/03/2026
Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 [...]
Allegro’s osteoarthritis hydrogel resolves lameness in animal study
12/03/2026
The hydrogel resolved lameness in 72% of horses treated Horses provide a strong translational model for human osteoarthritis Clinical investigation authorized by Belgian regulatory authority Allegro’s hydrogel is first- [...]
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
12/03/2026
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million [...]
Bavarian Nordic Publishes Annual Report 2025
12/03/2026
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, [...]
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
12/03/2026
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD [...]
BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026
11/03/2026
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
11/03/2026
ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company. Attachments notification-of-managers [...]
Nyxoah Participera à la 36ème Conférence Annuelle Oppenheimer Healthcare MedTech & Services
11/03/2026
Nyxoah Participera à la 36ème Conférence Annuelle Oppenheimer Healthcare MedTech & Services Mont-Saint-Guibert, Belgique – 11 mars 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » [...]
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
11/03/2026
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on [...]
RadNet, Inc. to Present at the 28th Annual Barclays Global Healthcare Conference on Thursday, March 12th
11/03/2026
LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT ), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced that [...]
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
11/03/2026
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast [...]
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
11/03/2026
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in [...]
LogicMark, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026
11/03/2026
LOUISVILLE, Ky., March 11, 2026 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK), a provider of emergency response systems, health communications devices, and technology for the growing personal safety and care economy, [...]
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
11/03/2026
-- Issues Statement in Response to DOMA’s Nomination of Director Candidates -- -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: [...]
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
11/03/2026
Nyxoah to Participate in the Oppenheimer 36 th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
11/03/2026
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports TN-301’s [...]
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
11/03/2026
PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial [...]

Pages